Novartis Ag

Novartis Pharma Gmbh

Paul David Greenspan

John Henry Van Duzer

Ruben Alberto Tommasi

Leslie Wighton McQuire

Scott Douglas Cowen

Eva Altmann

Claudia Betschart

Junichi Sakaki

Roger A Fujimoto

Rene Lattmann

Martin Missbach

Naoki Teno

Keigo Gohda

Miyuki Horiuchi

Michihiro Takai

Compounds of the formula (I), wherein R is aryl or biaryl; R is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C -C -alkyl in which C -C -alkyl is interrupted by Y; Y is O, S, SO, SO , CO or NR ; R is hydrogen or lower alkyl; or R and R combined are C -C -alkylene or C -C -alkylene interrupted by Y; R is hydrogen or lower alkyl; R is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C -C -alkyl in which C -C -alkyl is interrupted by Y; R is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitors

N-substituted peptidyl nitriles as cysteine cathepsin inhibitors

Dipeptide nitriles

Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity

Growing community of inventors

New Providence, NJ, United States of America

Paul David Greenspan